EyePoint Pharmaceuticals receives a reiterated sell rating due to ongoing clinical and commercial uncertainties despite recent progress in DME and wet AMD trials. Duravyu (EYP-1901) showed positive ...
President and Chief Executive Officer — Jay S. Duker, M.D. Chief Financial Officer — George O. Elston Chief Medical Officer — Ramiro Ribeiro, M.D. Management expects DuraVu to be the only tyrosine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback